复宏汉霖 | Henlius

Founded in 2009, Shanghai Henlius Biotech, Inc. (Henlius) is a global clinical-stage company focusing on the discovery, development, manufacturing and commercialization of high-quality and innovative biologics to treat a range of chronic and life-threatening diseases. With a team of over 600 employees in Shanghai, Beijing, Taipei and Bay Area, Henlius brings a combined leadership, global drug development and biologic manufacturing experience of 200+ years, and is determined to bring the meaningful therapeutic solutions for patients. For more information, please visit www.henlius.comHenlius pipeline includes 11 clinical-stage product candidates with 24 successful IND/CTA filings (14 approvals from China; 3 from the United States; 3 from Taiwan; 1 from the European Union; 1 from Ukraine; 1 from Philippines and 1 from Australia). In October 2017, Henlius submitted its first New Drug Application (NDA) of HLX01 (Rituximab Injection) to CFDA, which granted for priority review in early 2018, making HLX01 potentially the first approved biosimilar in China.